• About Us
    • Leadership
    • Our Supporters
    • IRS Form 990
  • Resources for Your Journey
    • What Is Heart Valve Disease?
    • Understanding Your Echocardiogram Results
    • News & Insights
    • HVV US Patient Journey Report
  • Events
  • Advocacy
    • Patient Spotlight Series
    • Apply to Be a Patient Ambassador
    • Share Your Story
    • Become an Advocate
    • HVD Policy Task Force
    • #Ask4Echo Campaign
  • Join Our Community
    • Sign Up For Our Mailing List
    • My Valve. My Voice.
Heart Valve Voice USHeart Valve Voice US
  • About Us
    • Leadership
    • Our Supporters
    • IRS Form 990
  • Resources for Your Journey
    • What Is Heart Valve Disease?
    • Understanding Your Echocardiogram Results
    • News & Insights
    • HVV US Patient Journey Report
  • Events
  • Advocacy
    • Patient Spotlight Series
    • Apply to Be a Patient Ambassador
    • Share Your Story
    • Become an Advocate
    • HVD Policy Task Force
    • #Ask4Echo Campaign
  • Join Our Community
    • Sign Up For Our Mailing List
    • My Valve. My Voice.

HVV Disease Policy Task Force Paper

Home Policy CenterComment LetterHVV Disease Policy Task Force Paper

HVV Disease Policy Task Force Paper

January 12, 2025 Comment Letter, Policy Center

Dear Administrator Brooks-LaSure,

As members of the Heart Valve Disease Policy Task Force, a national group of 30 leaders including clinician and patient advocates, we appreciate the opportunity to comment on the proposed decision memo for national coverage for Transcatheter Tricuspid Valve Replacement (TTVR). In particular, we wish to emphasize the critical importance of establishing a comprehensive Medicare coverage policy that includes all FDA-approved minimally invasive transcatheter devices to improve quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy. Such a policy is not only pivotal in addressing the unmet needs of Medicare beneficiaries suffering from tricuspid regurgitation but also in facilitating timely access to innovative and life-saving technologies.

Read full comment letter here.

Share
0

You also might be interested in

COVID-19: Consejos para pacientes con valvulopatías cardíacas

COVID-19: Consejos para pacientes con valvulopatías cardíacas

Mar 17, 2020

El COVID-19 (Coronavirus) supone un reto sin precedentes para la[...]

Pete Johnson

Pete Johnson

Oct 17, 2024

Can you share your experience with heart valve disease? It[...]

Christine Rekash

Christine Rekash

Apr 28, 2025

Can you share your experience with heart valve disease? I[...]

Contact Us

Please contact us with any questions or to get involved.

Send Message
Join the My Valve My Voice patient community Download the app
Sign Up for Our Mailing List
  • facebook
  • x
  • linkedin

© · Heart Valve Voice

Terms of Use
Privacy Policy

Website Management provided by Genacom

Contact Info

  • Heart Valve Voice US
  • 100 M Street SE 600 Washington, DC 20003
  • info@heartvalvevoice-us.org
  • https://www.heartvalvevoice-us.org
Prev Next